Page last updated: 2024-12-05

iohexol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iohexol is a non-ionic, water-soluble contrast medium, used primarily in X-ray imaging. Its chemical formula is C19H26I3N3O8. Iohexol was synthesized by adding iodine to an appropriate precursor molecule, and it is a relatively safe and well-tolerated contrast agent. Iohexol is used to improve the visibility of organs and structures in various medical imaging procedures like CT scans, MRI, and angiography. It works by increasing the density of the tissues or fluids it is injected into, allowing for better contrast in the image. The use of iohexol is essential for accurate diagnosis and treatment of a wide range of medical conditions, including cancers, infections, and cardiovascular diseases. The study of iohexol is important for understanding its pharmacokinetic properties, its potential adverse effects, and its interactions with other medications. Researchers are also looking at ways to optimize the use of iohexol for specific applications, such as targeted delivery to specific tissues or organs.'

Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3730
CHEMBL ID1200455
CHEBI ID31709
SCHEMBL ID26501
MeSH IDM0011673

Synonyms (129)

Synonym
AC-1934
MLS002153854
5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodo-n,n'-bis(2,3-dihydroxypropyl)isophthalamide
5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
omnipaque 240
nycodenz
omnipaque
brn 2406632
exypaque
1,3-benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
iohexolum [inn-latin]
einecs 266-164-2
win 39424
iohexol
PRESTWICK_802
66108-95-0
cas-66108-95-0
PRESTWICK2_000512
BSPBIO_000463
SMP1_000152
BPBIO1_000511
PRESTWICK3_000512
smr000857075
MLS001332586
MLS001332585
histodenz(tm), nonionic density gradient medium
n,n'-bis(2,3-dihydroxypropyl)-5-(n-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide
NCGC00166000-01
DB01362
omnipaque (tn)
iohexol (jp17/usp/inn)
D01817
BCBCMAP01_000051
SPBIO_002384
PRESTWICK0_000512
PRESTWICK1_000512
NCGC00166000-02
win-39424
CHEMBL1200455
nsc-759636
CHEBI:31709 ,
iohexolum
HMS1569H05
5-[acetyl(2,3-dihydroxypropyl)amino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5-[acetyl(2,3-dihydroxypropyl)amino]-n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
A835339
n1,n3-bis[2,3-bis(oxidanyl)propyl]-5-[2,3-bis(oxidanyl)propyl-ethanoyl-amino]-2,4,6-tris(iodanyl)benzene-1,3-dicarboxamide
HMS2096H05
iohexol 350
dtxsid6023157 ,
tox21_112286
dtxcid803157
HMS2235D07
S4531
histodenz
omnipaque 70
omnipaque 300
nsc 759636
iohexol [usan:usp:inn:ban:jan]
omnipaque 350
unii-4419t9mx03
omnipaque 210
omnipaque 140
omnipaque 180
ec 266-164-2
4419t9mx03 ,
FT-0627276
AKOS015895399
HMS3369O04
iohexol [ep monograph]
iohexol [who-dd]
iohexol [usp-rs]
iohexol [ep impurity]
iohexol [usp monograph]
iohexolum [who-ip latin]
iohexol [mart.]
oraltag
iohexol [who-ip]
iohexol [orange book]
iohexol [usan]
iohexol [vandf]
iohexol [mi]
iohexol [jan]
iohexol [inn]
1,3-benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo
CCG-220512
HY-B0594
SCHEMBL26501
tox21_112286_1
NCGC00166000-04
5-(n-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-n,n'-bis(2,3-dihydroxypropyl)isophthalamide
1,3-benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
I0903
n,n'-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoisophthalamide
5-(n-dhp-acetamido)-2,4,6-triiodo-n,n'-b is-dhp-isophthalami
1-n,3-n-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
iohexol, analytical standard
5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide
mfcd00077732
SR-01000838892-2
sr-01000838892
iohexol, united states pharmacopeia (usp) reference standard
iohexol, european pharmacopoeia (ep) reference standard
iohexol for peak identification, european pharmacopoeia (ep) reference standard
n1,n3-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
HMS3713H05
iohexol, pharmaceutical secondary standard; certified reference material
bdbm50247977
n1,n3-bis(2,3-dihydroxypropyl)-5-(n-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide
AS-12699
Q410683
AMY21804
BCP31800
nycodenz;omnipaque;exypaque
D91214
EN300-19628570
iohexol (ep monograph)
iohexol (mart.)
iohexol (usp-rs)
iohexol (ep impurity)
iohexol (usp monograph)
ioexolo
5-(acetyl((2rs)-2,3-dihydroxypropyl)amino)-n-((2rs)-2,3-dihydroxypropyl)-n'-((2sr)-2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide 5-(acetyl((2rs)-2,3-dihydroxypropyl)amino)-n,n'-bis((2sr)-2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarbo
iohexolum (inn-latin)
omnipaque 9
5-(acetyl(2,3-dihydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
v08ab02
iohexol (usan:usp:inn:ban:jan)
omnipaque 12

Research Excerpts

Overview

Iohexol is a typical iodinated radiocontrast medium and widely used in clinical angiography. Its clearance from serum or urine is used to measure glomerular filtration rate (GFR) Iohexol 350 is a  low osmolarity and competent intravenous countenance having minimum adverse reactions.

ExcerptReferenceRelevance
"Iohexol is a typical iodinated radiocontrast medium and widely used in clinical angiography. "( MRGPRX2 mediates immediate-type pseudo-allergic reactions induced by iodine-containing iohexol.
Che, D; Cheng, L; Li, T; Pan, B; Sun, M; Wu, D; Yuan, F; Zhang, C, 2021
)
2.29
"Iohexol is a commonly used second generation non-ionic iodinated contrast agent with a multitude of advantages such as low osmolarity and competent intravenous countenance having minimum adverse reactions. "( Albumin Based Iohexol Nanoparticles for Computed Tomography: An
Bendale, K; Chaudhari, P; Kale, T; Singh, KK, 2019
)
2.32
"Iohexol is a useful screening contrast agent and can safely provide information, and its use reduces the risk of aspiration and the chance of leakage of large amounts of barium."( The use of low-osmolar water-soluble contrast in videofluoroscopic swallowing exams.
Bartelt, D; Campion, M; Gayler, BW; Harris, JA; Hayes, A; Haynos, J; Herbick, S; Jones, B; Kling, T; Lingaraj, A; Singer, M; Smith, C; Starmer, H; Webster, K, 2013
)
1.11
"Iohexol is a nonradioactive contrast medium, and its clearance from serum or urine is used to measure glomerular filtration rate (GFR). "( Quantification of Iohexol in Serum by High-Performance Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
Haymond, S; Miller, A; Vespa, G; Vicente, FB, 2016
)
2.21
"Iohexol is a reference marker for glomerular filtration rate determination."( Performance of iohexol determination in serum and urine by HPLC: validation, risk and uncertainty assessment.
Cavalier, E; Chapelle, JP; Charlier, C; Delanaye, P; Dubois, N; Hubert, P; Krzesinski, JM; Rozet, E, 2008
)
1.42
"Iohexol is a nonradioactive marker that has been used successfully to test intestinal permeability in humans with inflammatory bowel disease. "( Estimation of intestinal permeability in healthy dogs using the contrast medium iohexol.
Coenen, M; Failing, K; Frias, R; Hewicker-Trautwein, M; Klenner, S; Spillmann, T; Ternes, W; Verspohl, J, 2009
)
2.02
"Iohexol is an iodinated contrast dye that has been shown to be useful in the estimation of glomerular filtration rate (GFR) in patients with suspected renal insufficiency. "( Ultraperformance liquid chromatography-tandem mass spectrometry assay for iohexol in human serum.
Annesley, TM; Clayton, LT, 2009
)
2.03
"Iohexol 350 is a satisfactory oral contrast agent for abdominopelvic CT. "( Prospective randomized trial of iohexol 350 versus meglumine sodium diatrizoate as an oral contrast agent for abdominopelvic computed tomography.
Heiken, JP; Lin, M; Peterson, CM; Pilgram, T,
)
1.86
"Iohexol is a safe contrast medium commonly used for medical imaging purposes and has been successfully applied more recently for the assessment of IP in animal models and humans."( Comparison of 51chromium-labeled ethylenediamine tetra-acetic acid and iohexol as blood markers for intestinal permeability testing in Beagle dogs.
Collado, MC; Frias, R; Sankari, S; Spillmann, T; Strube, K; Ternes, W; Westermarck, E, 2012
)
1.33
"Iohexol clearance is an accepted, but time-consuming assay for the measurement of glomerular filtration rate (GFR). "( Correct evaluation of renal glomerular filtration rate requires clearance assays.
Hjorth, L; Karpman, D; Wiebe, T, 2002
)
1.76
"Iohexol clearance is a valid method for measuring GFR in patients at any stages of renal failure. "( [Validity of iohexol clearance in patients with chronic renal failure and normal renal function in comparison to (99m)Tc-DTPA-clearance].
Fünfstück, R; Gottschild, D; Hartung, R; Keil, E; Stein, G; Wiendieck, E, 2003
)
2.13
"Iohexol (Omnipaque) is a non-ionic contrast media for neuroradiology, which causes the neurological complications on rare occasions. "( [Speech disturbance following myelography with iohexol: a case report].
Harada, T; Hayashi, T; Ishiyama, N; Miyazaki, H; Toda, Y, 2005
)
2.03
"Iohexol clearance is an accurate and precise exogenous marker of glomerular filtration rate (GFR), but protocols are generally lengthy or require multiple sampling. "( Validity of simplified protocols to estimate glomerular filtration rate using iohexol clearance.
Altmann, P; James, TJ; Levy, JC; Lewis, AV; Tan, GD; Taylor, RP, 2007
)
2.01
"Iohexol is a very satisfactory contrast medium for myelography and compared favorably with other non-ionic contrast media."( Clinical trial of iohexol in lumbar myelography.
Harrison, M; Kendall, B; Schneidau, A, 1983
)
1.32
"Iohexol is a recently synthesized non-ionic low-osmolar contrast medium. "( A controlled clinical trial of iohexol and diatrizoate in aortofemoral angiography.
Egsgaard, H; Hørup, A; Praestholm, J, 1983
)
1.99
"Iohexol is a very satisfactory contrast medium for myelography and compares favourably with other non-ionic contrast media."( Clinical trial of iohexol for lumbar myelography.
Harrison, M; Kendall, B; Schneidau, A; Stevens, J, 1983
)
1.32
"Iohexol is a nonionic water-soluble iodinated contrast medium with chemical and physical properties similar to those of metrizamide. "( Intravenous digital subtraction angiography with iohexol.
Bernstein, AD; Cacayorin, ED; Fruehan, CT; Kieffer, SA; Lee, SH,
)
1.83
"Iohexol is a new, nonionic water-soluble contrast agent undergoing early clinical trials in the United States. "( Neuroangiography with iohexol.
Bryan, RN; Miller, SL; Roehm, JO; Weatherall, PT,
)
1.89
"Iohexol is a safe, effective contrast agent when handled properly and causes less discomfort to patients than Conray 60."( Clinical trial of Iohexol vs. Conray 60 for cerebral angiography.
Fox, AJ; Pelz, D; Viñuela, F,
)
1.19
"Iohexol is a very satisfactory drug for all types of myelography."( Cervical myelography with iohexol.
Kendall, B; Stevens, J, 1984
)
1.29
"Iohexol is a new, nonionic contrast material that has been shown in animal studies to hold great promise as an agent for coronary arteriography and ventriculography with fewer adverse hemodynamic effects than standard ionic media. "( Hemodynamic and electrocardiographic effects in man of a new nonionic contrast agent (iohexol): advantages over standard ionic agents.
Bhargava, V; Bloomquist, JN; Higgins, CB; Lew, W; Mancini, GB; Shabetai, R; Slutsky, RA; Stein, JB, 1983
)
1.93
"Iohexol is a water-soluble contrast medium that is partly absorbed/permeated through mucosa of the small bowel and excreted unchanged in the urine. "( Increased urinary excretion of iohexol after enteral administration in patients with ileal Crohn's disease. A new test for disease activity.
Edgren, J; Halme, L; Linden, H; von Smitten, K, 1993
)
2.01
"Iohexol is a non-ionic contrast agent, which has been widely described in recent literature as an accurate marker for the measurement of glomerular filtration rate (GFR). "( Measurement of iohexol by capillary electrophoresis: minimizing practical problems encountered.
Des Parkin, J; Houlihan, C; Jenkins, MA; Jerums, G; Ratnaike, S, 2000
)
2.1
"Iohexol was found to be an efficacious myelographic contrast agent, with good to excellent myelograms in 93% of cases."( Iohexol for cervical myelography via C1-C2 puncture: study of efficacy and adverse reactions.
Latchaw, RE; Sackett, JF; Shaw, DD; Turski, PA,
)
2.3
"Iohexol 300 is a very suitable contrast medium for spinal angiography."( Spinal angiography with iohexol.
Kendall, B, 1986
)
1.3

Effects

Iohexol has been shown to have a remarkably low intravenous toxicity in mice and rats. Iohexol clearance has been proposed to estimate the glomerular filtration rate (GFR)

ExcerptReferenceRelevance
"Iohexol has a slightly higher osmolarity in comparison with iopamidol; therefore it might induce a more pronounced diuretic effect and then a better distension of the excretory pathway. "( [Quality control in urography with iopamidol and iohexol. A parallel comparison].
Abbona, M; Bazzocchi, M; Stacul, F; Ukovich, W; Zanella, F, 1987
)
1.97
"Iohexol clearance has been proposed to estimate the glomerular filtration rate (GFR). "( A single Bayesian estimator for iohexol clearance estimation in ICU, liver failure and renal transplant patients.
Åsberg, A; Barin-Le Guellec, C; Carrier, P; Destere, A; Ehrmann, S; Loustaud-Ratti, V; Marquet, P; Salmon Gandonnière, C; Woillard, JB, 2022
)
2.45
"Iohexol has clearly been shown to be well suited for urography in adults and may be the contrast medium of choice in pediatric urography."( Iohexol in urography. Survey and present state.
Ekelund, L, 1983
)
2.43
"Iohexol has been shown to have a remarkably low intravenous toxicity in mice and rats. "( Acute intravenous toxicity of iohexol in the mouse and in the rat.
Salvesen, S, 1980
)
1.99
"Iohexol (350 mg I/ml) has been compared with meglumine-Na-Ca metrizoate (370 mg I/ml) in selective coronary angiography in 37 adult patients. "( Iohexol in coronary angiography. A comparison of ionic and non-ionic contrast media.
Emanuelsson, H; Renaa, T; Selin, K, 1983
)
3.15
"Iohexol has the lowest chemotoxicity of any agent yet synthesized."( Chemotoxicity of contrast media and clinical adverse effects: a review.
Dawson, P,
)
0.85
"Iohexol has a slightly higher osmolarity in comparison with iopamidol; therefore it might induce a more pronounced diuretic effect and then a better distension of the excretory pathway. "( [Quality control in urography with iopamidol and iohexol. A parallel comparison].
Abbona, M; Bazzocchi, M; Stacul, F; Ukovich, W; Zanella, F, 1987
)
1.97

Actions

Iohexol did not cause increased glomerular permeability in steroid- and saline-pretreated rats. Iohexol gave a lower recurrence frequency (approximately 3.5 times) of reactions than ionic monomers in patients who previously experienced adverse reactions to vascular contrast media.

ExcerptReferenceRelevance
"Iohexol and CO2 produce less severe hepatic damage and are preferred to meglumine diatrizoate for hepatic injection."( Comparison of hepatic damage from direct injections of iodinated contrast agents and carbon dioxide.
Culp, WC; Hawkins, IF; Mladinich, CR, 1999
)
1.75
"Iohexol did not produce significant changes for any of the magnesium fractions."( Changes in serum magnesium during excretory urography. A comparison of ionic and nonionic contrast media.
Morris, TW; Prentice, LI; Sahler, LG; Segal, AJ, 1992
)
1
"Iohexol did not cause increased glomerular permeability in steroid- and saline-pretreated rats."( Pretreatment with steroids before intravenous injection of diatrizoate or iohexol. Effects on urine and serum profiles.
Goldman, K; Hemmingsen, L; Larsen, S; Skaarup, P; Svendsen, O; Thomsen, HS, 1991
)
1.23
"Iohexol gave a lower recurrence frequency (approximately 3.5 times) of reactions than ionic monomers in patients who previously experienced adverse reactions to vascular contrast media."( Adverse reactions following two separate intravascular injections of contrast media in the same patient. A comparison between iohexol and monomeric ionic media.
Andrew, E; Haider, T; Odegård, T; Sogn, EE,
)
1.06
"For iohexol the increase in coronary blood flow was small but significant: 12 +/- 7%, 25 +/- 11% and 38 +/- 16% for the 2, 4 and 6 ml administrations, respectively (mean +/- s.d.; p less than 0.01)."( Is nonionic isotonic iohexol the contrast agent of choice for quantitative myocardial videodensitometry?
Bos, HS; Pijls, NH; Uijen, GJ; Van der Werf, T, 1988
)
1.07
"Iohexol did not produce any epileptiform activity but epileptiform activity was detected in five patients receiving metrizamide."( Risk of seizures after myelography: comparison of iohexol and metrizamide.
Bach-Gansmo, T; Elmqvist, D; Maly, P, 1988
)
1.25
"Iohexol did not produce any significant changes in the contractile force."( Inotropic effects of ionic and nonionic contrast materials in isolated heart preparations.
Braveny, P; Juggi, JS; Telahoun, G; Yousof, AM, 1987
)
0.99
"Iohexol was seen to cause both less marked overall hemodynamic alterations and a lower incidence of significant changes in pressure and heart rate."( Comparison of an ionic with a nonionic contrast agent for cardiac angiography. Results of a multicenter trial.
Bettmann, MA; Higgins, CB,
)
0.85

Treatment

Iohexol had a similar low risk for developing clinically significant renal failure (0.9%) as ioxaglate. In iohexol-treated LLC-PK1 cells, rhEpo attenuated activation of caspase-3, 8 and 9.

ExcerptReferenceRelevance
"Iohexol-treated patients had a similar low risk for developing clinically significant renal failure (0.9%) as ioxaglate."( Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.
Hansell, P; Lagerqvist, B; Liss, P; Persson, PB, 2006
)
1.06
"In iohexol-treated LLC-PK1 cells, rhEpo attenuated activation of caspase-3 (p = 0.003), caspase-8 (p = 0.033) and caspase-9 (p = 0.055)."( Protective effect of erythropoietin against radiocontrast-induced renal tubular epithelial cell injury.
Jaber, BL; Kolyada, AY; Liangos, O; Madias, NE, 2008
)
0.86

Toxicity

No complications were seen, and the adverse effects, usually a feeling of warmth, were very minor with both contrast media. iohexol caused less discomfort than sodium metrizoate.

ExcerptReferenceRelevance
" The results of these studies demonstrate that ioversol is an effective, well tolerated and safe contrast agent for intravenous excretory urography."( Ioversol in intravenous excretory urography. Evaluation of radiographic quality, patient tolerance and safety in four clinical studies.
Jahn, H; Müller-Späth, R, 1992
)
0.28
" Therefore, the non-ionic and slightly hyperosmolaric iohexol may be less toxic to the kidneys than the ionic and hypertonic diatrizoate."( [Comparative study on nephrotoxicity of ionic and non-ionic contrast agents for drip infused urography].
Harada, T; Miyagata, S; Nishizawa, O; Noto, H; Shimoda, N; Sugaya, K; Suzuki, T; Tsuchida, S, 1992
)
0.53
" The calculated and experimental catheter tubing-chamber connection pressures were safe for both contrast media, at rates of 1 mL/second for long catheter tubing and 2 mL/second for short tubing."( Safety considerations in the power injection of contrast media via central venous catheters during computed tomographic examinations.
Carlson, JE; Halvorsen, RA; Hedlund, LJ; Ritenour, R; Trenkner, SW, 1992
)
0.28
"This study establishes that power injection of contrast media via a CVS during CT is a safe procedure."( Safety considerations in the power injection of contrast media via central venous catheters during computed tomographic examinations.
Carlson, JE; Halvorsen, RA; Hedlund, LJ; Ritenour, R; Trenkner, SW, 1992
)
0.28
" This difference was obscured in the previous studies by the pooling of RCTs in which the less toxic NIM were used and RCTs in which the more toxic ionic contrast medium ioxaglate was used."( Miscellaneous adverse effects of low-versus high-osmolality contrast media: a study revised.
Brismar, J; Jacobsson, BF; Jorulf, H, 1991
)
0.28
" Safety was assessed by monitoring vital signs (blood pressure, pulse and respiration), clinical laboratory studies and observation of adverse effects prior to and after injection of contrast medium."( A double blind clinical study comparing the safety, tolerance and efficacy of ioversol 240 and iohexol 240 (Omnipaque 240) in ascending venography.
Spinks, BC; Wilkins, RA, 1990
)
0.5
" The patients were questioned about adverse effects, and they underwent psychometric assessment and EEG-recordings: 11 had adverse effects, chiefly mild and exclusively transient, without sequelae."( Intracranial iohexol-distribution following cervical myelography, postmyelographic registration of adverse effects, psychometric assessment and electroencephalographic recording.
Eriksen, FB; Madsen, HH; Olsen, NK; Svare, U; Zeeberg, I, 1990
)
0.65
"A multicenter study of adverse effects of ionic and nonionic contrast agents was conducted in three similar time periods."( A prospective trial of ionic vs nonionic contrast agents in routine clinical practice: comparison of adverse effects.
Arenson, RL; Cross, AP; Wolf, GL, 1989
)
0.28
" Mechanisms of severe adverse reactions are reviewed, including the views of Lasser and Lalli, and the view that emphasizes the importance of cardiotoxic and hemodynamic effects."( Chemotoxicity of contrast media and clinical adverse effects: a review.
Dawson, P,
)
0.13
" When the acute intravenous toxicity of 35% I, wt/vol, ioversol was compared with 35% I, wt/vol, iohexol and 37% I, wt/vol, iopamidol in mice, no significant differences in LD50 values or general toxicity were found."( Acute and subacute toxicity studies of ioversol in experimental animals.
Blair, M; Coveney, J; Ralston, WH; Robbins, MS, 1989
)
0.49
" The safety of iohexol was assessed by monitoring adverse reactions and neurologic status and by measuring vital signs and serum laboratory values."( Lumbar myelography with iohexol in outpatients: prospective multicenter evaluation of safety.
Binet, EF; Gabrielsen, TO; Rosenbaum, AE; Wang, H, 1989
)
0.94
" There was only one adverse reaction in the entire study."( A double-blind comparative study of the safety, tolerability, and efficacy of ioversol and iohexol in peripheral and visceral arteriography.
Cutcliff, WB; Schwarten, DE, 1989
)
0.5
" Serious adverse reactions did not occur and none of the ambulatory patients required readmission because of side effects."( Side effects after ambulatory lumbar iohexol myelography.
Dale, LG; Myhr, G; Sand, T; Stovner, LJ; Tangerud, A, 1989
)
0.55
" Contrast phlebography with iohexol is a safe and comfortable procedure."( [The side effects of phlebography of the lower extremities using iohexol. A prospective study].
Biondetti, PR; Breda, F; Carta, M; Casara, D; Cogo, A; Corbetti, F; Prandoni, P; Tomasella, G; Vigo, M,
)
0.66
"Nephrotoxicity of radio-opaque contrast media (CM) is generally believed to involve toxic injury of proximal tubular cells."( Nephrotoxicity of high- and low-osmolality contrast media.
Avila, A; Dennis, B; Finnie, KJ; Jevnikar, AM; Linton, AL; Plummer, DT, 1988
)
0.27
"A prospective, controlled study was performed to compare side effect incidences after lumbar iohexol myelography (n = 97) and diagnostic lumbar puncture (n = 85)."( Side effects after diagnostic lumbar puncture and lumbar iohexol myelography.
Dale, L; Salvesen, R; Sand, T; Stovner, LJ, 1987
)
0.74
"Selective vertebral angiography was performed in 28 rabbits in order to compare the adverse effects of two monomeric (metrizamide, iohexol) and two dimeric (iodecol, 2-5410-3) non-ionic water-soluble contrast media."( The toxicity of non-ionic water-soluble contrast media in selective vertebral angiography. An experimental study in rabbits with special reference to the difference between monomeric and dimeric compounds.
Aulie, A; Skalpe, IO, 1985
)
0.47
"Nonionic contrast media have been proven safe for intrathecal opacification, but adverse effects, including psycho-organic syndrome and asterixis, have been reported and appear more frequently when contrast medium enters intracranial spaces."( Iohexol: a new nonionic contrast medium for myelography and cisternography with markedly reduced neurotoxicity.
Gonsette, RE; Liesenborghs, L,
)
1.57
" Under adverse conditions, high doses and high concentrations of iohexol produced little arachnoiditis, while metrizamide produced mild to moderate arachnoiditis."( Intrathecal toxicity of iohexol vs. metrizamide. Survey and current state.
Haughton, VM,
)
0.68
" Adverse effects of contrast media on kidney function include diuresis, changes in renal blood flow, osmotic nephroses, albuminuria, enzymuria and, most important, glomerular filtration rate."( Contrast media-induced nephrotoxicity. Survey and present state.
Almén, T; Golman, K,
)
0.13
" No complications were seen, and the adverse effects, usually a feeling of warmth, were very minor with both contrast media, but iohexol caused less discomfort than sodium metrizoate."( Comparison of side effects during cerebral computed tomography with a nonionic (iohexol) and an ionic (metrizoate) contrast medium.
Hordvik, M; Skalpe, IO,
)
0.56
" The hyperosmolar, ionic contrast medium, meglumine metrizoate, was far more toxic to the endothelium than the nonionic media, metrizamide and iohexol, which are far less hyperosmolar."( Human endothelial cell culture as an evaluation system for the toxicity of intravascular contrast media.
Börsum, T; Laerum, F; Reisvaag, A,
)
0.33
"Selective left vertebral angiography was carried out in 25 rabbits comparing the toxic effects of iohexol and metrizamide (Amipaque)."( The toxicity of the non-ionic water-soluble contrast media iohexol and metrizamide (Amipaque) in selective vertebral angiography. An experimental study in rabbits.
Skalpe, IO, 1981
)
0.72
" It is concluded that iobitridol is a safe and effective contrast medium."( Assessment of the safety and efficacy of iobitridol, an iodinated contrast medium (30% iodine), in cranial CT.
Moseley, I; Taylor, W, 1995
)
0.29
" Clinically severe adverse renal events were uncommon (N = 15) and did not differ in incidence between contrast groups (iohexol N = 6; diatrizoate N = 9)."( Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study.
Cohen, MB; Goldfarb, S; Halpern, EF; Hill, JA; Ludbrook, PA; Murphy, MJ; Rudnick, MR; VanFossen, DB; Wexler, L; Winniford, M, 1995
)
0.72
" Adverse reactions were sought, physical examinations were performed, and standard hematology and serum chemistry values were measured before and 1 day after injection; a 72-hour serum creatinine level was also measured."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.29
" Mild adverse reactions were experienced by 10% of patients; there were no significant differences in reaction rates among contrast agents."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.29
"Iopromide at a dose of approximately 300 mg I/kg is safe and effective as an excretory urographic agent and is comparable in performance with ioversol and iopamidol."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.29
" Adverse events were monitored by investigators, and efficacy was evaluated by grading the radiographic images."( Safety and efficacy of iopromide in cerebral arteriography.
Drayer, BP; Haughton, VM; Hilal, SK; Hyland, D; Maravilla, K; Osborn, AG; Papke, RA, 1994
)
0.29
"Most adverse events were mild or moderate in severity; all resolved completely."( Safety and efficacy of iopromide in cerebral arteriography.
Drayer, BP; Haughton, VM; Hilal, SK; Hyland, D; Maravilla, K; Osborn, AG; Papke, RA, 1994
)
0.29
"These study results indicate that iopromide is a safe and effective contrast medium for cerebral angiography."( Safety and efficacy of iopromide in cerebral arteriography.
Drayer, BP; Haughton, VM; Hilal, SK; Hyland, D; Maravilla, K; Osborn, AG; Papke, RA, 1994
)
0.29
" Minor adverse clinical experiences were noted in 23% of the iopromide group versus 20% of the comparator group."( Double-blind study of the safety, tolerance, and diagnostic efficacy of iopromide as compared with iopamidol and iohexol in patients requiring aortography and visceral angiography.
Athanasoulis, C; Bron, K; Cope, C; Druy, EM; Faykus, MH; Hedgcock, M; Miller, FJ, 1994
)
0.5
"The purpose of this study was to determine if the selective use of low-osmolality contrast material for excretory urography and CT is safe and if it saves money."( Selective use of low-osmolality contrast agents for i.v. urography and CT: safety and effect on cost.
Duval, JF; Dye, J; Hunter, TB, 1994
)
0.29
"The use of the newest nonionic, water-soluble, low-osmolar radiographic contrast media (CM) is still associated with occasional adverse reactions affecting the neural tissues."( Neurotoxicity of nonionic low-osmolar contrast media. A receptor binding study.
Bernasconi, P; Fiori, MG; Mennini, T, 1993
)
0.29
"Because of the small number of visceral angiography procedures performed (38), no definitive conclusions could be drawn as to the differences between ionic and nonionic agents regarding grade-2 and grade-3 adverse events."( Safety of nonionic agents in visceral angiography.
Enge, IP, 1993
)
0.29
"The efficacy and adverse reactions of iobitridol versus iohexol in contrast-enhanced CT (CECT) of the head were investigated."( Efficacy and safety of iobitridol versus iohexol for contrast-enhanced CT of the head.
Caille, JM; Clarisse, J; Drouillard, J; Frija, G; Froment, JC; Gandon, Y; Gaston, A, 1996
)
0.81
" The incidence of adverse events was similar in both groups (11."( Efficacy and safety of iobitridol versus iohexol for contrast-enhanced CT of the head.
Caille, JM; Clarisse, J; Drouillard, J; Frija, G; Froment, JC; Gandon, Y; Gaston, A, 1996
)
0.56
"Iobitridol is a safe and efficient contrast agent in urography."( Clinical safety and efficacy of iobitridol in urography.
Bakker, AJ; Falke, TH; Meiss, L; Van Waes, PF, 1996
)
0.29
" Clinical safety was evaluated by recording the adverse events observed during investigation and by the patient's assessments."( Safety and efficacy of the new iodinated nonionic low-osmolality contrast medium Iobitridol (Xenetix) in coronary and ventricular angiography.
Aliot, E; Ethevenot, B; Funck, F; Lefevre, T, 1996
)
0.29
" Four patients experienced an adverse event, 2 in each group."( Safety and efficacy of the new iodinated nonionic low-osmolality contrast medium Iobitridol (Xenetix) in coronary and ventricular angiography.
Aliot, E; Ethevenot, B; Funck, F; Lefevre, T, 1996
)
0.29
" Nature,onset,intensity as well as outcome of each adverse reaction was reported."( Safety and efficacy of Xenetix, a new iodinated contrast agent, in pediatric angiocardiography.
Chantepie, A; Losay, J; Lusson, JR; Rossignol, AM, 1996
)
0.29
"Iobitridol is a safe and effective contrast agent for pediatric angiocardiography."( Safety and efficacy of Xenetix, a new iodinated contrast agent, in pediatric angiocardiography.
Chantepie, A; Losay, J; Lusson, JR; Rossignol, AM, 1996
)
0.29
" Outcome variables were pain, image quality and adverse events."( [Contrast media in peripheral angiography: does cost reduction mean loss of quality and safety? A reevaluation based on a randomized double-blind comparative study of ioxaglate versus iopromide].
Farres, MT; Lammer, J; Thurnher, S; Wildling, R; Winkelbauer, F; Woessmer, B, 1996
)
0.29
" Mild adverse events were observed more frequently in ioxaglate angiography (11% vs."( [Contrast media in peripheral angiography: does cost reduction mean loss of quality and safety? A reevaluation based on a randomized double-blind comparative study of ioxaglate versus iopromide].
Farres, MT; Lammer, J; Thurnher, S; Wildling, R; Winkelbauer, F; Woessmer, B, 1996
)
0.29
" However, an increase of mild adverse reactions up to 11% to 15% has to be accepted."( [Contrast media in peripheral angiography: does cost reduction mean loss of quality and safety? A reevaluation based on a randomized double-blind comparative study of ioxaglate versus iopromide].
Farres, MT; Lammer, J; Thurnher, S; Wildling, R; Winkelbauer, F; Woessmer, B, 1996
)
0.29
"We report our experience in the safe use of power injectors with central and small-gauge peripheral venous access devices for intravenous administration of contrast agent to children undergoing computed tomography (CT) examinations."( Safe use of power injectors with central and peripheral venous access devices for pediatric CT.
Kaste, SC; Young, CW, 1996
)
0.29
"In light of the low frequency of complications, power injectors and central venous access devices or small-gauge butterfly catheters are safe systems for delivery of intravenous contrast material to pediatric patients."( Safe use of power injectors with central and peripheral venous access devices for pediatric CT.
Kaste, SC; Young, CW, 1996
)
0.29
" It is safe to withhold long-term anticoagulants if a normal angiogram is obtained in this subgroup of patients with clinically suspected pulmonary embolism."( Feasibility, safety and clinical utility of angiography in patients with suspected pulmonary embolism.
Batchelor, DA; Brandjes, DP; Büller, HR; Reekers, JA; van Beek, EJ, 1996
)
0.29
" Regarding iodinated contrast media (CM), LD50 tests were used extensively in the past."( Preclinical safety assessment of contrast media: predictive value.
Karlsson, JO, 1996
)
0.29
"Documentation of main adverse effects, their magnitudes and relationship to contrast concentrations in patients subjected to myelography under basic radiographic facilities."( Myelography with Omnipaque (Iohexol) using basic radiographic facilities: the main adverse effects.
Kazema, RR; Ndosi, BN; Ndosi, NK, 1996
)
0.59
" The main adverse effects were assessed in both groups (subjects) by a neuro-physician unaware of subject status."( Myelography with Omnipaque (Iohexol) using basic radiographic facilities: the main adverse effects.
Kazema, RR; Ndosi, BN; Ndosi, NK, 1996
)
0.59
"Even with limited radiographic facilities, myelography with Omnipaque 240 is relatively safe; being associated with no more adverse effects than a medical diagnostic lumbar puncture; thus the contrast concentration of choice for myelography under sub-optical radiographic set up."( Myelography with Omnipaque (Iohexol) using basic radiographic facilities: the main adverse effects.
Kazema, RR; Ndosi, BN; Ndosi, NK, 1996
)
0.59
" The incidence of adverse events was similar and low for both contrast media."( Image quality and safety after iodixanol in intravenous urography; a comparison with iohexol.
Almén, T; Bååth, L; Hougens Grynne, B; Kjaersgaard, P; Sundgren, PC; Törnquist, C, 1996
)
0.52
" Clinical safety was assessed by the reporting of adverse events and diagnostic efficacy was evaluated."( Evaluation of the clinical safety and efficacy of iobitridol (Xenetix) in intravenous urography.
Fournier, PJ; Freitag, P; Steinbrich, W; Voegeli, E, 1996
)
0.29
" Specifically, frequency of adverse events (AEs), subjective change in quality of diagnostic information, and quantitative enhancement characteristics were compared."( Iopentol (Imagopaque 300) compared with iopromide (Ultravist 300) in abdominal CT. A multi-centre monitoring trial assessing adverse events and diagnostic information--results from 518 patients in Spain.
Encina, JL; Martí-Bonmatí, L; Rodríguez, V; Ronchera-Oms, CL, 1997
)
0.3
" No adverse events were observed among the children below 1 year of age."( Iopentol (Imagopaque 300) compared with iohexol (Omnipaque 300) and diatrizoate (Urografin 292) in pediatric urography. A clinical trial assessing adverse events and diagnostic information.
Brekke, O; Lanning, P, 1997
)
0.56
" There were no statistically significant differences between numbers of patients reporting adverse events nor number of patients reporting discomfort in the two groups."( Iopentol (Imagopaque 350) compared with iohexol (Omnipaque 350) in pediatric cardioangiography. A clinical trial assessing adverse events, ECG, blood pressure and diagnostic information.
De Greef, D; Kunnen, M; Skinningsrud, K, 1997
)
0.56
" ECG, blood pressure, heart rate, adverse events and efficacy were evaluated."( Iopentol (Imagopaque 300) compared with iopromide (Ultravist 300) in pediatric angiocardiography. A clinical trial assessing adverse events, ECG and diagnostic information.
Aggoun, Y; Iserin, L; Kachaner, J; Piéchaud, JF; Skinningsrud, K, 1997
)
0.3
" Two patients (5%) in each group reported contrast-related adverse events other than a sensation of heat, while three patients in the iopentol group and four in the iohexol group reported procedure-related adverse events."( Iopentol (Imagopaque 300 and 350) compared with iohexol (Omnipaque 300 and 350) in cerebral and aortic arch angiography. A clinical trial assessing adverse events and diagnostic information.
Bjartveit, K; Ericsson, K, 1997
)
0.75
"Iodixanol 270 mg I/ml causes significantly less injection-associated pain during femoral arteriography and is as safe and efficacious as iopromide 300 mg I/ml."( Injection-associated pain in femoral arteriography: a European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide.
Downes, M; Grynne, BH; Justesen, P; Lang, H; Rasch, W; Seim, E,
)
0.13
" With modern contrast media and technique, pulmonary angiography is a safe procedure."( Pulmonary angiography: a safe procedure with modern contrast media and technique.
Carlsson, A; Mâre, K; Nilsson, T, 1998
)
0.3
" Adverse events, including injection associated discomfort, were recorded during and up to 24 h after the examination."( Iodixanol in paediatric excretory urography: efficiency and safety compared to iohexol.
Amar, C; Boscq, M; Chateil, JF; Dacher, J; Garel, C; Hassan, M; Sirinelli, D, 1998
)
0.53
"No serious adverse event occurred in any of the three groups."( Iodixanol in paediatric excretory urography: efficiency and safety compared to iohexol.
Amar, C; Boscq, M; Chateil, JF; Dacher, J; Garel, C; Hassan, M; Sirinelli, D, 1998
)
0.53
"The authors compare the toxic effects of iobitridol and iohexol, which are nonionic contrast media with equivalent osmolalities and viscosities on the kidney."( Comparative toxic effects of iobitridol and iohexol on the kidney.
Gemba, M; Kawamura, H; Satoh, Y; Shimada, M; Sugimoto, J; Tanaka, E; Wasaki, M, 1998
)
0.81
"These findings suggest that iobitridol has significantly less toxic effects on the kidney compared with iohexol under the condition of our experiment."( Comparative toxic effects of iobitridol and iohexol on the kidney.
Gemba, M; Kawamura, H; Satoh, Y; Shimada, M; Sugimoto, J; Tanaka, E; Wasaki, M, 1998
)
0.78
" Renal function parameters and adverse events were recorded for one week after the urography."( Assessment of possible nephrotoxicity from iohexol in patients with normal and impaired renal function.
Hietala, SO; Holmberg, G; Jakobsson, G; Lithner, F; Lundqvist, S; Skinningsrud, K; Stegmayr, B, 1998
)
0.56
" Nine patients experienced adverse events but none of them required any treatment."( Assessment of possible nephrotoxicity from iohexol in patients with normal and impaired renal function.
Hietala, SO; Holmberg, G; Jakobsson, G; Lithner, F; Lundqvist, S; Skinningsrud, K; Stegmayr, B, 1998
)
0.56
" Some minor adverse events were recorded."( Assessment of possible nephrotoxicity from iohexol in patients with normal and impaired renal function.
Hietala, SO; Holmberg, G; Jakobsson, G; Lithner, F; Lundqvist, S; Skinningsrud, K; Stegmayr, B, 1998
)
0.56
" With regards to cell viability, transmonolayer resistance and inulin permeability the radiocontrast agents with reduced osmolality were significantly less toxic than diatrizoate, independent of their ionic strength."( Comparative cytotoxicity of ionic and non-ionic radiocontrast agents on MDCK cell monolayers in vitro.
Haller, C; Schick, CS, 1999
)
0.3
" Results of this study demonstrate that ioversol-350 is diagnostically effective, well tolerated and safe when used for selective coronary arteriography with left ventriculography."( A double-blind study comparing the safety, tolerability, and efficacy of ioversol-350 and iohexol-350 in coronary arteriography with left ventriculography.
McGaughey, MD; Remetz, MS; Sharf-Bornhofen, E,
)
0.35
"In five dogs with normal renal function, doses of 200, 400, 600 and 800 mg of iodine/kg bodyweight of iohexol (350 mg of iodine/ml) were assessed in comparison to a dose of 880 mg of iodine/kg bodyweight of meglumine-sodium amidotrizoate (370 mg of iodine/ml) to determine the hematologic and biochemical parameters, urinalysis and urinary osmolality, pulse and respiratory rates, and adverse effects were determined."( [The adverse effects of the water-soluble iodinated contrast media used in excretory urography in the canine species].
Agut Giménez, A; Hita Rosino, E; Sánchez-Valverde García, MA, 1999
)
0.52
"The HOCM, diatrizoate, was more toxic to rat kidneys than the LOCM iohexol; PLA2, LPO and calcium load played a role in producing renal function impairment induced by diatrizoate meglumine; amlodipine protected the renal tissue from nephrotoxicity induced by diatrizoate."( Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model.
Duan, SB; Liu, FY; Liu, RH; Luo, JA; Peng, YM; Wu, HW; Yang, XL, 2000
)
0.54
"Most studies of the adverse effects of x-ray contrast media used in ERCP have focused on post-ERCP pancreatitis."( Comparative cytotoxicity of low-osmolar nonionic and high-osmolar ionic contrast media to dog gallbladder epithelial cells.
Ju, YM; Kim, JY; Kim, MH; Lee, SK; Min, YI; Seo, DW, 2002
)
0.31
" The frequency of adverse events was lower for patients receiving iodixanol."( Iodixanol in paediatric gastrointestinal imaging: safety and efficacy comparison with iohexol.
Carty, HM; Friis, M; Kampenes, VB; Klaveness, AJ; Petersen, KK; Sprigg, A; Stake, G; Wright, NB, 2002
)
0.54
"For 2 years, we prospectively recorded all adverse events temporally associated with the administration of iopromide in 29,508 consecutive patients undergoing contrast-enhanced CT at our institution."( Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital.
Mortelé, KJ; Oliva, MR; Ondategui, S; Ros, PR; Silverman, SG, 2005
)
0.33
" One hundred eighty-eight adverse events (89%) were rated mild, 19 moderate (9%), and four severe (2%), including one fatality."( Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital.
Mortelé, KJ; Oliva, MR; Ondategui, S; Ros, PR; Silverman, SG, 2005
)
0.33
"The purpose of this study was to review the rate of adverse events after contrast medium administration in the general population and at-risk patients (renal impairment, heart failure (NYHA III or IV), hypotension or hypertension, coronary artery disease, previous reaction to contrast media, asthma and/or allergies, dehydration, diabetes mellitus, poor general condition) under daily practice conditions in a post-marketing surveillance study."( Safety of iobitridol in the general population and at-risk patients.
Hammerstingl, R; Honold, E; Mohajeri, H; Vogl, TJ; Wolf, M, 2006
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"Gadolinium-based contrast agents can be used in diagnostic and interventional angiography, and are safe in recommended doses in patients with impaired renal function, but the image quality is usually unsatisfactory."( Safety of gadodiamide mixed with a small quantity of iohexol in patients with impaired renal function undergoing coronary angiography.
Barcin, C; Isik, E; Iyisoy, A; Kose, S; Kursaklioglu, H; Tore, HF, 2006
)
0.58
"To prospectively evaluate adverse events (AEs) in patients who underwent nonionic monomeric or dimeric contrast media-enhanced computed tomography (CT) and to compare these effects with AEs in patients who underwent unenhanced CT."( Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial.
Böhm, I; Hübner-Steiner, U; Kuhl, CK; Schild, HH; Speck, U, 2006
)
0.33
" Both contrast agents were safe in that no severe AEs and only a few moderate AEs were observed."( Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial.
Böhm, I; Hübner-Steiner, U; Kuhl, CK; Schild, HH; Speck, U, 2006
)
0.33
" From the FDA databases, we evaluated 18 adverse event terms associated with renal injury or dysfunction after CM use."( Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects.
Dumouchel, W; Solomon, R, 2006
)
0.33
"To evaluate the frequency of adverse events and possible risk factors after the administration of an intravenous contrast medium (CM), iobitridol, in a large multicentre postmarketing surveillance study."( Intravenous contrast media in uroradiology: evaluation of safety and tolerability in almost 50,000 patients.
Alken, P; Knoll, T; Michel, MS; Peters, CR; Rotert, H; Trojan, L; Wendt-Nordahl, G, 2006
)
0.33
" Age, sex, indication for the actual examination and adverse events were documented."( Intravenous contrast media in uroradiology: evaluation of safety and tolerability in almost 50,000 patients.
Alken, P; Knoll, T; Michel, MS; Peters, CR; Rotert, H; Trojan, L; Wendt-Nordahl, G, 2006
)
0.33
"9% of the patients experienced acute adverse events that were non-serious and transient."( Intravenous contrast media in uroradiology: evaluation of safety and tolerability in almost 50,000 patients.
Alken, P; Knoll, T; Michel, MS; Peters, CR; Rotert, H; Trojan, L; Wendt-Nordahl, G, 2006
)
0.33
"Iobitridol is clinically safe and well tolerated in urography as demonstrated in this study of a large patient population, producing mainly minor symptoms as adverse events."( Intravenous contrast media in uroradiology: evaluation of safety and tolerability in almost 50,000 patients.
Alken, P; Knoll, T; Michel, MS; Peters, CR; Rotert, H; Trojan, L; Wendt-Nordahl, G, 2006
)
0.33
"To evaluate the incidence of adverse events with the universal use of iodixanol for computed tomography (CT) and compare it with periods when iohexol was used exclusively."( Adverse events with universal use of iodixanol for CT: comparison with iohexol.
Ho, AL; O'Malley, ME; Tomlinson, GA,
)
0.57
" Immediate and delayed adverse events were seen in 76 and 40 patients (0."( Adverse events with universal use of iodixanol for CT: comparison with iohexol.
Ho, AL; O'Malley, ME; Tomlinson, GA,
)
0.36
" However, the incidence of immediate and delayed adverse events was significantly higher with iodixanol than iohexol."( Adverse events with universal use of iodixanol for CT: comparison with iohexol.
Ho, AL; O'Malley, ME; Tomlinson, GA,
)
0.58
"Exposure to iodinated contrast media may elicit a variety of adverse reactions."( Iodide mumps after contrast media imaging: a rare adverse effect to iodine.
Bircher, AJ; Gilgen-Anner, Y; Heim, M; Ledermann, HP, 2007
)
0.34
" The important role of iodine in this adverse reaction is demonstrated."( Iodide mumps after contrast media imaging: a rare adverse effect to iodine.
Bircher, AJ; Gilgen-Anner, Y; Heim, M; Ledermann, HP, 2007
)
0.34
" A percutaneous cervical approach allows a low risk of pharyngoesophageal structure injury and is considered a safe diagnostic technique in dynamic imaging studies."( The safety zone of percutaneous cervical approach: a dynamic computed tomographic study.
Jeong, BO; Kim, KT; Lee, GK; Lee, JH; Lee, SH; Seo, EM; Suk, KS, 2007
)
0.34
" There were no serious adverse events (SAEs)."( A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopaedic surgery patients with spinal anaesthesia.
Fagrell, B; Keipert, PE; Nygårds, EB; Olofsson, C; Ponzer, S; Przybelski, R; Winslow, N; Winslow, RM, 2008
)
0.35
" LOCM was less toxic to rat kidneys than HOCM."( The protective role of telmisartan against nephrotoxicity induced by X-ray contrast media in rat model.
Duan, SB; Liu, FY; Peng, YM; Wang, P; Wang, YH; Xu, XQ; Zou, Q, 2009
)
0.35
" The secondary endpoints are absolute and relative increases in sCr of at least 50%, thrombolysis in myocardial infarction (TIMI) perfusion grade, and major adverse cardiac events at 1, 6, and 12 months."( The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Grotti, S; Liistro, F; Limbruno, U; Picchi, A; Pierli, C, 2010
)
0.36
" Adverse events were documented and the image quality was assessed."( Safety and tolerability of iobitridol in general and in patients with risk factors: results in more than 160,000 patients.
Freyhardt, P; Hamm, B; Heine, O; Maurer, M; Schnapauff, D; Wolf, M, 2011
)
0.37
" The adverse event rate (e."( Safety and tolerability of iobitridol in general and in patients with risk factors: results in more than 160,000 patients.
Freyhardt, P; Hamm, B; Heine, O; Maurer, M; Schnapauff, D; Wolf, M, 2011
)
0.37
"Iobitridol was shown to be a safe and well-tolerated contrast medium with a low incidence of adverse events in patients with and without risk factors resulting in a good or excellent image quality in most patients."( Safety and tolerability of iobitridol in general and in patients with risk factors: results in more than 160,000 patients.
Freyhardt, P; Hamm, B; Heine, O; Maurer, M; Schnapauff, D; Wolf, M, 2011
)
0.37
" It is a safe procedure and more cost effective than a negative exploration or diagnostic laparoscopy."( Is herniography useful and safe?
Hureibi, KA; Kidambi, AV; McLatchie, GR, 2011
)
0.37
" To assess the toxic effects of non-ionic CM on the glomerular and aortic endothelial cells, iopromide and iodixanol, two kinds of representative non-ionic CM, were used for the in vivo study."( Toxic effects of a high dose of non-ionic iodinated contrast media on renal glomerular and aortic endothelial cells in aged rats in vivo.
Chen, B; Chen, L; Jia, E; Jia, Q; Li, C; Tao, Z; Wang, L; Xu, Z; Yang, Z; Zhao, Y; Zhu, T, 2011
)
0.37
" No device-related issues or adverse events were observed."( A preclinical study of the safety and efficacy of Occlusin™ 500 Artificial Embolization Device in sheep.
Biliske, JA; Griffith, IJ; Nation, PN; Owen, RJ; Polakowski, R; Tiege, PB, 2012
)
0.38
"8%) patients, there were reports of adverse drug reactions (ADRs) excluding tolerance indicators (TIs) (i."( Safety and diagnostic image quality of iopromide: results of a large non-interventional observational study of European and Asian patients (IMAGE).
Heinsohn, C; Kwon, ST; Lengsfeld, P; Liang, CH; Palkowitsch, P; Stauch, K; Zhang, SX, 2012
)
0.38
"49%) reported an adverse drug reaction (ADR) and 1983 patients (1."( Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients.
Bostelmann, S; Lengsfeld, P; Palkowitsch, PK, 2014
)
0.4
"The purpose of the study is to examine the incidence of adverse reactions caused by non-ionic contrast media in selected patients after desensitization treatment and to evaluate the safety profile of organ iodine contrast media (i."( Safety profile and protocol prevention of adverse reactions to uroangiographic contrast media in diagnostic imaging.
Brunese, L; D'Amora, M; D'Andrea, A; Di Grezia, G; Grassi, R; Mandato, Y; Reginelli, A; Rossi, C; Rotondi, A,
)
0.13
"The novel DEB is safe and has a favorable vascular healing response on neointimal hyperplasia."( Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis.
An, X; Du, R; Han, H; Ni, J; Ying, C; Zhang, J; Zhang, R; Zhu, J; Zhu, Z, 2015
)
0.42
" Secondary outcomes included safety (30-day incidence of major adverse cardiovascular events (MACE)) and length of stay in the ED."( Efficiency and safety of coronary CT angiography compared to standard care in the evaluation of patients with acute chest pain: a Canadian study.
Dennie, C; Inacio, J; Peña, E; Peterson, R; Rubens, F; Stiell, I, 2016
)
0.43
"The relative incidence of long-term adverse effects between low-osmolar contrast media (LOCM) and iso-osmolar contrast media (IOCM) after coronary angiography is still unclear."( Long-Term Adverse Effects of Low-Osmolar Compared With Iso-Osmolar Contrast Media After Coronary Angiography.
Chang, D; Ju, S; Lu, CQ; Tang, A; Wang, YC; Zhang, SJ, 2016
)
0.43
"Gastrointestinal toxicity is the most common adverse effect of chemotherapy."( Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats.
Forsgård, RA; Frias, R; Holma, R; Korpela, R; Lindén, J; Österlund, P; Spillmann, T, 2016
)
0.73
"The presence of iodinated X-ray contrast media (ICM) in source waters is of high concern to public health because of their potential to generate highly toxic disinfection by-products (DBPs)."( The impact of iodinated X-ray contrast agents on formation and toxicity of disinfection by-products in drinking water.
Duirk, SE; Jeong, CH; Machek, EJ; Plewa, MJ; Richardson, SD; Shakeri, M; Ternes, TA; Wagner, ED, 2017
)
0.46
" Since iopamidol was significantly more toxic than iohexol in human MSCs, a more careful examination of safety of radiocontrast dyes for clinical use is warranted."( Cytotoxicity of radiocontrast dyes in human umbilical cord mesenchymal stem cells.
Bakshi, S; Beeravolu, N; McKee, C; Perez-Cruet, M; Rasul Chaudhry, G; Thibodeau, B; Wilson, G, 2018
)
0.73
" To evaluate the safety of the procedure, we aimed to review all immediate adverse reactions that could be related to iohexol administration in our group's 25 years worth of experience."( Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience.
Aparicio, MC; Cannata, A; Carrara, F; Diadei, O; Ferrari, S; Gaspari, F; Perico, N; Perna, A; Remuzzi, G; Ruggenenti, P; Stucchi, N; Thakar, S; Trillini, M, 2018
)
1.09
"Iohexol administration for GFR measurement is a safe procedure, even in repeated investigations in the same subject, that should be adopted in clinical research and, when needed, also in clinical practice."( Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience.
Aparicio, MC; Cannata, A; Carrara, F; Diadei, O; Ferrari, S; Gaspari, F; Perico, N; Perna, A; Remuzzi, G; Ruggenenti, P; Stucchi, N; Thakar, S; Trillini, M, 2018
)
2.33
" Intravenous provocation with a skin test-negative RCM is safe and enables identification of a tolerated alternative RCM."( Radiocontrast Media Hypersensitivity: Skin Testing Differentiates Allergy From Nonallergic Reactions and Identifies a Safe Alternative as Proven by Intravenous Provocation.
Behle, V; Brockow, K; Stoevesandt, J; Trautmann, A,
)
0.13
"25 mL) was well-tolerated in NZ white rabbits, with no adverse inflammation or irritation."( Next tier in vitro and in vivo nonclinical studies further elucidating the safety and toxicity profile of MB-102, a novel fluorescent tracer agent for measurement of glomerular filtration rate.
Bugaj, JE; Dorshow, RB, 2019
)
0.51
"49%) experienced an adverse event (AE), and 24 patients (0."( Safety Analysis of Iobitridol as a Nonionic Contrast Medium: A Postmarketing Multicenter Surveillance Study With 94,960 Patients Almost 20 Years After Introduction.
Collettini, F; Darmon-Kern, E; Gorodetski, B; Hamm, B; Heine, O; Penzkofer, T; Wolf, M, 2020
)
0.56
"Iobitridol is a safe contrast medium with a high tolerability and efficacy."( Safety Analysis of Iobitridol as a Nonionic Contrast Medium: A Postmarketing Multicenter Surveillance Study With 94,960 Patients Almost 20 Years After Introduction.
Collettini, F; Darmon-Kern, E; Gorodetski, B; Hamm, B; Heine, O; Penzkofer, T; Wolf, M, 2020
)
0.56
"5% dextrose dialysis solution is chemically stable, meeting the criteria set forth in the standards and guidelines of the US Pharmacopeia and the Institute of Safe Medication Practices."( Compatibility and stability of non-ionic iodinated contrast media in peritoneal dialysis solution and safe practice considerations for CT peritoneography.
Badugu, SK; Crabtree, JH; Gellens, ME; Kaushal, A; Mancini, A; Rappai, J, 2023
)
0.91
" However, little information was available about whether ICM-derived DBPs are toxic to aquatic organisms."( Disinfection byproducts of iopamidol, iohexol, diatrizoate and their distinct acute toxicity on Scenedesmus sp., Daphnia magna and Danio rerio.
Liu, H; Watson, P; Yang, F; Yang, X; Zhou, N, 2023
)
1.18

Pharmacokinetics

The pharmacokinetic properties of iohexol, in combination with its low toxicity, make it a suitable agent for determination of glomerular filtration rate in clinical practice. The objective of this work was to investigate the use of a hybrid machine learning/population pharmacokinetics approach to improve individual io hexol clearance estimation.

ExcerptReferenceRelevance
"Four nonionic contrast media (iohexol, iopamidol, iopromide, and iosimide) are compared in this clinical study in their pharmacokinetic behavior with an ionic reference preparation (meglumine diatrizoate)."( Pharmacokinetics of iohexol, iopamidol, iopromide, and iosimide compared with meglumine diatrizoate.
Hartwig, P; Mützel, W; Taenzer, V, 1989
)
0.89
" The pharmacokinetic properties of iohexol, in combination with its low toxicity, make it a suitable agent for determination of glomerular filtration rate in clinical practice."( Contrast media and glomerular filtration: dose dependence of clearance for three agents.
Bäck, SE; Krutzén, E; Nilsson-Ehle, P, 1988
)
0.55
" The biologic half-life was 121 minutes, comparable with that of other intravascular contrast media."( Human pharmacokinetics of iohexol. A new nonionic contrast medium.
Andrew, E; Aulie, A; Olsson, B; Sveen, K,
)
0.43
" The mean apparent first-order terminal elimination (gamma-phase) half-life was 12."( Pharmacokinetics of iohexol, a new nonionic radiocontrast agent, in humans.
Edelson, J; Palace, G; Shaw, D, 1984
)
0.59
" Cefcanel renal clearance and fraction excreted in the urine were linearly correlated with renal function and thus, logarithmic increases in plasma area under the concentration versus time curve and plasma elimination half-life were seen with decreasing GFR."( Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function.
Dahl, K; Edwall, B; Slettevold, L; Thurmann-Nielsen, E; Torrång, A; Walstad, R, 1994
)
0.29
"Computed tomography enhancement data of the aorta and/or the liver obtained after injecting a conventional ionic and a nonionic contrast agent were used to calculate pharmacokinetic parameters and to simulate the time course of enhancement for a variety of different infusion regimens modifying contrast medium strength, dose, and injection rate."( Application of pharmacokinetics to computed tomography: injection rates and schemes: mono-, bi-, or multiphasic?
Krause, W, 1996
)
0.29
" A "crossover" prediction of data was possible within the range of interindividual variations of pharmacokinetic parameters and thus validated the chosen approach of computer simulation."( Application of pharmacokinetics to computed tomography: injection rates and schemes: mono-, bi-, or multiphasic?
Krause, W, 1996
)
0.29
" Plasma clearance was calculated by dividing the dose of marker with the area under the plasma concentration curve (AUC) from the time of injection to infinity using one-compartment (ClAUC-slope) and three-compartment (ClAUC-3comp) models."( Clearance of iohexol, chromium-51-ethylenediaminetetraacetic acid, and creatinine for determining the glomerular filtration rate in pigs with normal renal function: comparison of different clearance techniques.
Almén, T; Chai, CM; Frennby, B; Jönsson, BA; Månsson, S; Sterner, G, 1996
)
0.66
" These data were used to calculate pharmacokinetic parameters such as half-lives, mean residence times, and areas under the curve with a computer program."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
" The computer program allowed for excellent fitting curves to the measured attenuation values and for subsequent calculation of pharmacokinetic parameters."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
"The pharmacokinetic parameters evaluated might be useful in the optimization of dosing and scanning parameters of the abdomen for ultrafast and helical CT."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
" The results were subject to pharmacokinetic analysis using compartment model-independent and -dependent methods."( Pharmacokinetics and tolerability of iopromide 240 after lumbar myelography.
Krause, W; Kugoev, AI; Timerbaeva, SL; Wegener, R, 1999
)
0.3
"After lumbar myelography, iopromide 240 is almost completely excreted renally within 72 hours, with a prolonged half-life as a result of the route of administration."( Pharmacokinetics and tolerability of iopromide 240 after lumbar myelography.
Krause, W; Kugoev, AI; Timerbaeva, SL; Wegener, R, 1999
)
0.3
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The validated method has been successfully applied to a pharmacokinetic study of thermosensitive liposome-encapsulated lomustine containing iohexol and lomustine solution after intravenous administration to C6 glioma rats."( HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats.
Derendorf, H; Gao, J; Li, M; Liu, C; Yu, F; Zeng, Y; Zhang, B; Zhuang, L, 2011
)
0.77
"We developed a detailed, whole-body physiologically based pharmacokinetic (PBPK) modeling tool for calculating the distribution of pharmaceutical agents in the various tissues and organs of a human or animal as a function of time."( BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.
Graf, JF; Scholz, BJ; Zavodszky, MI, 2012
)
0.38
" A population pharmacokinetic model was developed from the index set and validated using standard methods."( New sampling strategy using a Bayesian approach to assess iohexol clearance in kidney transplant recipients.
Alnajjar, A; Andres, CR; Barbet, C; Benz-de Bretagne, I; Blasco, H; Büchler, M; Gatault, P; Halimi, JM; Le Guellec, C; Lebranchu, Y; Vourcʼh, P, 2012
)
0.62
" A noncompartmental approach was used for pharmacokinetic analysis."( Comparison of pharmacokinetic variables for creatinine and iohexol in dogs with various degrees of renal function.
Balouka, D; Biourge, V; Collignon, CM; Concordet, D; Craig, AJ; Eliassen, KA; Faucher, MR; Harran, NX; Heiene, R; Lefebvre, HP; Queau, Y; Reynolds, BS; Risøen, U, 2012
)
0.62
"7 mL/min/kg) and a significantly lower mean volume of distribution at steady state (250 ± 37 mL/kg vs 539 ± 73 mL/kg), mean residence time (80 ± 31 minutes vs 195 ± 73 minutes), and mean elimination half-life (74 ± 20 minutes vs 173 ± 53 minutes)."( Comparison of pharmacokinetic variables for creatinine and iohexol in dogs with various degrees of renal function.
Balouka, D; Biourge, V; Collignon, CM; Concordet, D; Craig, AJ; Eliassen, KA; Faucher, MR; Harran, NX; Heiene, R; Lefebvre, HP; Queau, Y; Reynolds, BS; Risøen, U, 2012
)
0.62
" Therefore, the pharmacokinetic properties of the CA possess a central role: iodinated x-ray CAs are small molecules that distribute rapidly within the extravascular extracellular space, whereas larger macromolecular compounds have a prolonged vascular phase and a restricted volume of distribution."( Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics.
Grenacher, L; Jost, G; Pietsch, H, 2013
)
0.39
" We aimed to provide a population pharmacokinetic (popPK) model of iohexol by re-evaluating data from the Berlin Initiative Study (BIS) to compare respective clearance estimates to the Schwartz approach and to assess the impact of revised clearance estimates on the BIS equations."( Using a three-compartment model improves the estimation of iohexol clearance to assess glomerular filtration rate.
Ebert, N; Fuhr, U; Martus, P; Schaeffner, E; Taubert, M; van der Giet, M, 2018
)
0.96
" The dataset was split into two groups, one to develop the population pharmacokinetic (POPPK) model (n = 103) and the other (n = 48) to estimate the predictive performances of the various GFR estimation methods."( Assessment of the glomerular filtration rate (GFR) in kidney transplant recipients using Bayesian estimation of the iohexol clearance.
Barbet, C; Barin-Le Guellec, C; Benz-de Bretagne, I; Besombes, J; Blasco, H; Büchler, M; Gatault, P; Halimi, JM; Riff, C, 2020
)
0.77
" To address potential concerns that iohexol administered during a course of chemotherapy impacts that therapy, we performed in vitro and in vivo pharmacokinetic drug-drug interaction evaluations of iohexol."( Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Beumer, JH; Christner, S; Chu, E; Guo, J; Holleran, JL; Ivy, SP; Joshi, A; Kiesel, B; Miller, BM; Parise, RA; Taylor, S; Venkataramanan, R, 2020
)
1.07
" Measuring GFR with iohexol to better dose carboplatin is unlikely to alter the safety or efficacy of chemotherapy through pharmacokinetic drug-drug interactions."( Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Beumer, JH; Christner, S; Chu, E; Guo, J; Holleran, JL; Ivy, SP; Joshi, A; Kiesel, B; Miller, BM; Parise, RA; Taylor, S; Venkataramanan, R, 2020
)
1.12
" We developed a population pharmacokinetic model and limited sampling schedules, implemented in the online InsightRX precision dosing platform, to facilitate pragmatic iohexol GFR assessment."( Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting.
Dalton, RN; Dam, RE; de Fijter, JW; de Vries, APJ; Engbers, AGJ; Guchelaar, HJ; Keizer, RJ; Moes, DJAR; Swen, JJ; van der Boog, PJM; Zwart, TC, 2021
)
1.12
" Assuming a varying number of random effects, we re-estimated previously developed population pharmacokinetic two- and three-compartment models in a model development group comprising 546 patients with iohexol concentration data up to 300 min post injection."( Advancement of pharmacokinetic models of iohexol in patients aged 70 years or older with impaired kidney function.
Ebert, N; Fuhr, U; Lösment, A; Martus, P; Schaeffner, E; Taubert, M; van der Giet, M, 2021
)
1.08
"Full pharmacokinetic data (7-12 samples) from 172 patients receiving iohexol for measurement of their GFR (unstable and stable ICU patients, liver failure patients and kidney transplant patients) were split into development (n = 136) and validation (n = 36) datasets."( A single Bayesian estimator for iohexol clearance estimation in ICU, liver failure and renal transplant patients.
Åsberg, A; Barin-Le Guellec, C; Carrier, P; Destere, A; Ehrmann, S; Loustaud-Ratti, V; Marquet, P; Salmon Gandonnière, C; Woillard, JB, 2022
)
1.24
"Maximum a posteriori Bayesian estimation (MAP-BE) based on a limited sampling strategy and a population pharmacokinetic model is frequently used to estimate pharmacokinetic parameters in individuals, however with some uncertainty (bias)."( A Hybrid Model Associating Population Pharmacokinetics with Machine Learning: A Case Study with Iohexol Clearance Estimation.
Åsberg, A; Carrier, P; Destere, A; Ehrmann, S; Gandonnière, CS; Guellec, CB; Loustaud-Ratti, V; Marquet, P; Premaud, A; Woillard, JB, 2022
)
0.94
"The objective of this work was to investigate the use of a hybrid machine learning/population pharmacokinetic approach to improve individual iohexol clearance estimation."( A Hybrid Model Associating Population Pharmacokinetics with Machine Learning: A Case Study with Iohexol Clearance Estimation.
Åsberg, A; Carrier, P; Destere, A; Ehrmann, S; Gandonnière, CS; Guellec, CB; Loustaud-Ratti, V; Marquet, P; Premaud, A; Woillard, JB, 2022
)
1.14
"7 h) using a population pharmacokinetic model we recently developed in Monolix and obtained using all the concentration timepoints available."( A Hybrid Model Associating Population Pharmacokinetics with Machine Learning: A Case Study with Iohexol Clearance Estimation.
Åsberg, A; Carrier, P; Destere, A; Ehrmann, S; Gandonnière, CS; Guellec, CB; Loustaud-Ratti, V; Marquet, P; Premaud, A; Woillard, JB, 2022
)
0.94

Compound-Compound Interactions

Iohexol is unlikely to affect the clinical pharmacokinetics of carboplatin, paclitaxel, gemcitabine, or other agents used in combination withcarboplatin treatment.

ExcerptReferenceRelevance
"To demonstrate the pelvic peritoneal recesses during voiding, evacuation proctography was combined with positive contrast peritoneography."( Evacuation proctography combined with positive contrast peritoneography to demonstrate pelvic floor hernias.
Bartram, CI; Halligan, S,
)
0.13
"To investigate the risk factors for local tumor progression after radiofrequency (RF) ablation combined with chemoembolization for the treatment of hepatocellular carcinoma (HCC)."( Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas 5 cm or smaller: risk factors for local tumor progression.
Fuke, H; Murata, K; Nakatsuka, A; Shiraki, K; Takaki, H; Takeda, K; Yamakado, K, 2007
)
0.34
"RA monitoring combined with spontaneous respiration to trigger image acquisition in CTPA produces optimal contrast enhancement in pulmonary arterial structures with minimal venous filling even with reduced doses of CA."( Optimizing computed tomography pulmonary angiography using right atrium bolus monitoring combined with spontaneous respiration.
Li, J; Li, W; Lun-Hou, D; Wang, M; Zhai, R, 2015
)
0.42
"To evaluate the feasibility of CT angiography of lower extremities by using 100 kVp as tube voltage and Iodixanol(270 mg I/ml) as contrast medium combined with iDose(4) iterative reconstruction technique."( [Applied research of CT angiography of lower extremities by using 100 kVp and iodixanol(270 mg I/ml) combined with iDose(4) iterative reconstruction technique].
Chen, B; Cheng, J; He, H; Kong, Q; Xiong, S; Xu, L; Xu, X; Yan, Z, 2015
)
0.42
"Using 100 kVp and Iodixanol (270 mg I/ml) combined with iDose(4) -4 iterative reconstruction technique for CT angiography of lower extremities, the image quality could meet the requirement for clinical diagnosis, the radiation dose and the volume of contrast medium could be lowered."( [Applied research of CT angiography of lower extremities by using 100 kVp and iodixanol(270 mg I/ml) combined with iDose(4) iterative reconstruction technique].
Chen, B; Cheng, J; He, H; Kong, Q; Xiong, S; Xu, L; Xu, X; Yan, Z, 2015
)
0.42
"The study aimed to prospectively evaluate the radiation dose reduction potential and image quality (IQ) of a high-concentration contrast media (HCCM) injection protocol in combination with a low tube current (mAs) in coronary computed tomography angiography."( Evaluation of a High Concentrated Contrast Media Injection Protocol in Combination with Low Tube Current for Dose Reduction in Coronary Computed Tomography Angiography: A Randomized, Two-center Prospective Study.
Hua, Y; Jin, X; Li, C; Mao, D; Shi, K; Sun, Y; Wang, M; Xu, J, 2017
)
0.46
"HCCM combined with low tube current allows dose reduction in coronary computed tomography angiography and does not compromise IQ."( Evaluation of a High Concentrated Contrast Media Injection Protocol in Combination with Low Tube Current for Dose Reduction in Coronary Computed Tomography Angiography: A Randomized, Two-center Prospective Study.
Hua, Y; Jin, X; Li, C; Mao, D; Shi, K; Sun, Y; Wang, M; Xu, J, 2017
)
0.46
"BACKGROUND This study is to investigate the feasibility of low iodine concentration contrast material (CM) combined with low tube voltage and adaptive statistical iterative reconstruction (ASIR) in renal computed tomography angiography (CTA)."( Low-Dose Scanning Technology Combined with Low-Concentration Contrast Material in Renal Computed Tomography Angiography (CTA): A Preliminary Study.
Fan, J; He, J; Li, W; Liu, S; Sheng, H; Shi, H; Sun, H, 2017
)
0.46
"To investigate the feasibility of iterative model reconstruction (IMR) combined with low tube voltage, low iodine load, and low iodine deliver rate in craniocervical computed tomography angiography (CTA)."( Feasibility study of iterative model reconstruction combined with low tube voltage, low iodine load, and low iodine delivery rate in craniocervical CT angiography.
Cai, W; Cheng, B; Gong, J; Hu, C; Hu, S; Shi, D; Wang, X; Zhang, W, 2018
)
0.48
" To address potential concerns that iohexol administered during a course of chemotherapy impacts that therapy, we performed in vitro and in vivo pharmacokinetic drug-drug interaction evaluations of iohexol."( Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Beumer, JH; Christner, S; Chu, E; Guo, J; Holleran, JL; Ivy, SP; Joshi, A; Kiesel, B; Miller, BM; Parise, RA; Taylor, S; Venkataramanan, R, 2020
)
1.07
"Iohexol is unlikely to affect the clinical pharmacokinetics of carboplatin, paclitaxel, gemcitabine, or other agents used in combination with carboplatin treatment."( Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Beumer, JH; Christner, S; Chu, E; Guo, J; Holleran, JL; Ivy, SP; Joshi, A; Kiesel, B; Miller, BM; Parise, RA; Taylor, S; Venkataramanan, R, 2020
)
2.24

Bioavailability

ExcerptReferenceRelevance
" It is not likely, that such a low dose of poorly absorbed drug would cause any adverse effects in the infant, unless it is hypersensitive to the drug already."( Excretion of iohexol and metrizoate in human breast milk.
Andrew, E; Hafsahl, G; Matheson, I; Nielsen, ST; Rasmussen, JN; Skinnemoen, K,
)
0.5
" Subdural deposition of the contrast medium and 51Cr-ethylenediaminetetraacetic acid resulted in a faster absorption rate and higher achieved blood levels than a subarachnoid injection of the two substances, where a slow absorption to lower blood concentrations was observed."( Absorption after subarachnoid and subdural administration of iohexol, 51Cr-EDTA, and 125I-albumin to rabbits.
Holtz, E; Jacobsen, T; Michelet, AA,
)
0.37
"Hypofractionated radiotherapy of rectal cancer leads to an increased tumor perfusion as reflected by an elevated K(trans), possibly improving the bioavailability of cytotoxic agents in rectal tumors, often administered early after radiotherapy treatment."( Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings.
Aerts, HJ; Backes, WH; Buijsen, J; Janssen, MH; Kierkels, RG; Lambin, P; Lammering, G; Ollers, MC, 2010
)
0.36
" Compared with non-heated group, the bioavailability of lomustine was obviously increased in C6 glioma rat plasma."( HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats.
Derendorf, H; Gao, J; Li, M; Liu, C; Yu, F; Zeng, Y; Zhang, B; Zhuang, L, 2011
)
0.57
" DCBs carry an active drug and a nonpolymeric carrier molecule or excipient that enhance the bioavailability of the drug to the vessel wall."( Drug-coated percutaneous balloon catheters.
Betala, JV; LaBerge, M; Langan Iii, EM, 2014
)
0.4
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The dehydration duration and the iohexol dosage were found to be the two most important factors to develop a rat CIN model. We developed a population pharmacokinetic model and limited sampling schedules, implemented in the online InsightRX precision dosing platform.

ExcerptRelevanceReference
" Sixty patients were divided into two groups of 30 patients; one group received Omnipaque in a dosage of 350 mgI/ml and the other group received Telebrix in a dosage of 350 mgI/ml."( Comparative trial of Omnipaque 350 (iohexol) and Telebrix 350 (sodium-meglumine-ioxithalamate) in left ventriculography and coronary arteriography.
Buis, B; Jorgova, J; Sedney, MI; van Benthem, A; van der Wall, EE,
)
0.41
" The dosage of contrast medium (350 mg I/ml) was 700 mg I/kg body weight."( Renal effects of iopentol and iohexol after intravenous injection.
Berg, KJ; Jakobsen, JA; Kolbenstvedt, AN, 1991
)
0.57
" Their dosage schedule was based on the physiological parameters of age, sex, body weight and renal function."( Low dose intravenous urography: results and technique modifications.
Keenan, RJ; Kengsakul, C; List, A, 1990
)
0.28
"01) in the 15-20 minute images of the calyx and pelvis of the kidney and urinary bladder in particular, this suggested the high usefulness of 100 ml dosing for the imaging diagnosis."( [Examination by densitometer on visualization of non-ionic contrast medium (iohexol) in excretory urography. 2. Changes in visualization by DIP].
Hamashima, T; Ikeuchi, T; Sakamoto, M, 1990
)
0.51
" At considerably smaller dosages, a dose-dependent increase in the left anterior descending artery diameter was seen with substance P; maximal dilation occurred at a dosage of 11."( Substance P dilates epicardial coronary arteries and increases coronary blood flow in humans.
Crossman, DC; Davies, GJ; Fuller, RW; Larkin, SW; Maseri, A, 1989
)
0.28
" An increase of the dosage resulted in a statistically significant improvement of the quality of the radiographic visualization."( Iopromide dosage and urographic image quality: is there an optimal dose?
Dominik, R; Keysser, R; Taenzer, V, 1989
)
0.28
" We conclude that image quality in nonselective, intra-arterial DSA can be improved without an increase in iodine dosage by the rapid administration of undiluted contrast material in small volumes."( Nonselective digital subtraction angiography. Compact contrast material bolus for improved image quality.
Alvarado, R; Palmaz, JC; Rees, CR; Reuter, SR, 1989
)
0.28
" Initially, iohexol 180 mgI/ml was used in dosage proportional to body weight varying between 5 ml and 15 ml."( Iohexol in paediatric myelography. An open non-comparative trial.
Kendall, B, 1986
)
2.09
" In the case of iopentol, a dose-response study was performed, 1 ml x 3 and 4 ml x 3 being also tested."( The influence of non-ionic contrast media on the endothelium of small arteries. A comparison of metrizamide, iohexol and iopentol.
Stjernquist, U; Wieslander, JB, 1987
)
0.49
" A dose-response curve for the release of glycosaminoglycan by chymopapain was linear when the amount of enzyme was plotted on a logarithmic scale against glycosaminoglycan release."( Effect of X-ray contrast media on the action of chymopapain on the intervertebral disc: an in vitro study of cartilage degradation.
Barrett, AJ; Buttle, DJ; Tudor, J, 1984
)
0.27
"9 months) in 52 patients with hepatocellular carcinoma (HCC): An emulsion of Lipiodol and epirubicin was injected as selectively as possible in a dosage proportional to liver function and tumour size."( [The chemoembolization of hepatocellular carcinoma: the computed tomographic findings and clinical results in prospective repetitive therapy].
Brambs, HJ; Claussen, CD; Dette, S; Dietz, K; Duda, SH; Geissler, F; Huppert, PE; Lauchart, W, 1994
)
0.29
" The contrast medium was injected rapidly into an antecubital vein within 2-3 min in most cases, using a standard dosage of 1 ml kg-1 body weight."( Iomeprol versus iopromide for intravenous urography.
de Geeter, P; Melchior, H, 1994
)
0.29
" Although steady state kinetics were not performed our findings suggest that a dosage reduction is not necessary even in pre-uraemic patients."( Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function.
Dahl, K; Edwall, B; Slettevold, L; Thurmann-Nielsen, E; Torrång, A; Walstad, R, 1994
)
0.29
" Because adjustments in drug dosing are often based on estimated values of renal function, it is important to define which, if any, of the available models, is appropriate for a specific patient population."( Predictive performance of renal function estimate equations in renal allografts.
Goerdt, PJ; Heim-Duthoy, KL; Macres, M; Swan, SK, 1997
)
0.3
" Dose-response (0."( Percutaneous computed tomography lymphography in the rabbit by subcutaneously injected nanoparticulates.
Bacon, ER; Cooper, ER; Gazelle, GS; Haley, PJ; McIntire, GL; Toner, JL; Wolf, GL, 1994
)
0.29
" New dosage regimens also could be simulated successfully."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
"The pharmacokinetic parameters evaluated might be useful in the optimization of dosing and scanning parameters of the abdomen for ultrafast and helical CT."( Application of pharmacokinetics to electron-beam tomography of the abdomen.
Baumgartner, C; Gröll, R; Kern, R; Krause, W; Rienmüller, R, 1999
)
0.3
" When optimal bolus timing was performed, higher vessel enhancement was observed during bolus first pass with iobitridol (iodine dosage 250 mg I/kg) compared with P743 (150 mg I/kg)."( CT pulmonary angiography with a macromolecular contrast medium: a comparative study versus iobitridol in rabbits.
Berthezene, Y; Canet, E; Corot, C; Violas, X; Wiart, M, 2001
)
0.31
" However, the relatively high radiation dosage of an additional CTP requires a strict indication regiment in patients with a negative CTA."( [A differentiated approach to the diagnosis of pulmonary embolism and deep venous thrombosis using multi-slice CT].
Günther, RW; Haage, P; Mahnken, AH; Schaller, S; Sinha, AM; Stargardt, A; Wildberger, JE, 2002
)
0.31
" Mean total volume of iohexol administered to dogs that had seizures was significantly higher, compared with that administered to dogs that did not have seizures, although dosage did not differ between groups."( Risk factors associated with development of seizures after use of iohexol for myelography in dogs: 182 cases (1998).
Barone, G; Shofer, FS; Steinberg, SA; Ziemer, LS, 2002
)
0.87
" The main outcome measures were diagnostic utility, incidence of alternative diagnoses, requirement for further imaging, length of hospital stay, urological intervention rates, radiation dosage and costs."( Renal colic: a prospective evaluation of non-enhanced spiral CT versus intravenous pyelography.
Anderson, JE; Arnold-Reed, DE; Bulsara, MK; Kuan, M; Mander, J; Mendelson, RM; Sweetman, G; Wedderburn, AW, 2003
)
0.32
" No adjustment of the recommended PO dosage of ramipril is needed in dogs with moderate renal impairment."( Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.
Jeunesse, E; Laroute, V; Lefebvre, HP; Toutain, PL,
)
0.13
" With the blood pool agent, similar contrast enhancement to the conventional agent was achieved with about 36% reduced dosage of iodine per body weight (mg I/kg)."( Comparison of liver perfusion parameters studied with conventional extravascular and experimental intravascular CT contrast agents.
Häkkinen, AM; Halavaara, J; Kapanen, M, 2007
)
0.34
"Estimation of glomerular filtration rate (eGFR) is essential in the diagnosis and monitoring of patients with kidney disease and for correct dosage of drugs eliminated from the circulation by the kidneys."( Estimated glomerular filtration rate (eGFRCystC) from serum cystatin C shows strong agreement with iohexol clearance in patients with low GFR.
Flodin, M; Hansson, LO; Jonsson, AS; Larsson, A, 2007
)
0.56
" The data clearly show that the ozonation of iopromide using a common applied ozone dosage leads to the formation of numerous iodinated transformation products, which are detectable by LC-ESI-MS."( Ozonation and reductive deiodination of iopromide to reduce the environmental burden of iodinated X-ray contrast media.
Jekel, M; Miehe, U; Putschew, A; Tellez, AS, 2007
)
0.34
" Iohexol clearance measured before and 24 h after dosing was unaffected."( A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopaedic surgery patients with spinal anaesthesia.
Fagrell, B; Keipert, PE; Nygårds, EB; Olofsson, C; Ponzer, S; Przybelski, R; Winslow, N; Winslow, RM, 2008
)
1.26
" In conclusion, the contrast effect varies with different contrast media formulations, even when the same iodine dosage is administered."( Effect of contrast media formulation on computed tomography angiographic contrast enhancement.
Iwasaki, T; Kishimoto, M; Miyake, Y; Shimizu, J; Tsuneda, R; Yamada, K,
)
0.13
"The objective of this study was to determine an optimal oral iohexol dosage for an intestinal permeability serum test (IPST) and to use the test to estimate intestinal permeability in healthy dogs."( Estimation of intestinal permeability in healthy dogs using the contrast medium iohexol.
Coenen, M; Failing, K; Frias, R; Hewicker-Trautwein, M; Klenner, S; Spillmann, T; Ternes, W; Verspohl, J, 2009
)
0.82
"Using the iohexol dosage established in this study, the iohexol IPST was easy to perform as a marker for intestinal permeability in dogs."( Estimation of intestinal permeability in healthy dogs using the contrast medium iohexol.
Coenen, M; Failing, K; Frias, R; Hewicker-Trautwein, M; Klenner, S; Spillmann, T; Ternes, W; Verspohl, J, 2009
)
0.98
" After the mask image had been taken, the contrast medium was administered using a dosage of 1ml/kg body weight at a rate of 4ml/s."( Evaluation of contrast-enhanced digital mammography.
Bick, U; Diekmann, F; Diekmann, S; Fallenberg, EM; Fischer, T; Freyer, M; Pöllinger, A, 2011
)
0.37
"The aim of this research was to study the gastrointestinal transit and gastric emptying of non-disintegrating solid dosage forms in rats using X-ray imaging."( Gastro intestinal tracking and gastric emptying of solid dosage forms in rats using X-ray imaging.
Brandeis, R; Karton, Y; Rosner, A; Saphier, S, 2010
)
0.36
" This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis."( Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.
Abtahi, S; Ajami, G; Amoozgar, H; Basiratnia, M; Borzouee, M; Cheriki, S; Derakhshan, A; Mohamadi, M; Soltani, M, 2010
)
0.57
" So HR, gender, TCD and weight can be used to adjust flow rate and dosage of contrast media before administration of contrast media during coronary CT angiography."( Factors influencing delay time and coronary arterial density during coronary angiography with DSCT.
Dogra, V; Tang, J; Tang, L; Wang, D; Xu, H; Xu, Y; Yu, T; Zhu, X, 2011
)
0.37
" Subsequently, Han Wistar rats (8 per group) received an intravenous injection of iso-osmolar CA (iodixanol) or low-osmolar CA (iopromide) at a dosage of 4 gI/kg body weight."( Changes of renal water diffusion coefficient after application of iodinated contrast agents: effect of viscosity.
Hütter, J; Jost, G; Lengsfeld, P; Lenhard, DC; Pietsch, H; Sieber, MA, 2011
)
0.37
" Given a range of built-in features and its inherent flexibility to customization, the model can be used to study a variety of pharmacokinetic and pharmacodynamic problems such as the effects of inter-individual differences and disease-states on drug pharmacokinetics and pharmacodynamics, dosing optimization, and inter-species scaling."( BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.
Graf, JF; Scholz, BJ; Zavodszky, MI, 2012
)
0.38
" Only one patient showed renal failure, one week after dosing with iodixanol."( Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
Chen, Y; Fu, G; Gao, C; Gao, W; He, B; He, Q; Hu, S; Liu, H; Liu, S; Liu, Y; Qi, X; Qiu, C; Su, X; Wang, J; Wang, L; Wang, M; Yang, P; Zhao, R; Zheng, X; Zheng, Y; Zhou, S, 2012
)
0.38
" CM dosage calculation was randomly categorized into groups: a BW group and a BW-BMI group."( Dual-source CT coronary angiography involving injection protocol with iodine load tailored to patient body weight and body mass index: estimation of optimal contrast material dose.
Tang, L; Xu, H; Xu, Y; Yang, G; Zhu, X; Zhu, Y, 2013
)
0.39
" The CAs were administered intravenously at a dosage of 4 g iodine/kg body weight."( The effect of iodinated contrast agent properties on renal kinetics and oxygenation.
Frisk, AL; Jost, G; Lengsfeld, P; Lenhard, DC; Pietsch, H, 2013
)
0.39
" The trial dosed with strain I-24 showed better IOPr removal than the un-dosed one."( Isolation and identification of an iopromide-degrading strain and its application in an A2/O system.
Gao, P; He, J; Hu, J; Liu, K; Liu, Y; Ognier, S; Xu, B; Xue, G, 2013
)
0.39
" On the basis of phantom measurements for the low-kilovolt CTA protocols, the iodine dosage was adjusted to 150 mg iodine/kg (70 kV) and 210 mg iodine/kg (90 kV)."( Optimizing contrast media injection protocols in state-of-the art computed tomographic angiography.
Flohr, TG; Jost, G; Korporaal, JG; Lell, MM; Mahnken, AH; Pietsch, H; Uder, M, 2015
)
0.42
" ARF was induced by the subcutaneous administration of cisplatin (5 mg/kg); IoCl and InCl were determined simultaneously, and plasma creatinine (pCreat) dosage was measured colorimetrically."( Iohexol clearance for determination of glomerular filtration rate in rats induced to acute renal failure.
Câmara, NO; Mastroianni-Kirsztajn, G; Nishida, SK; Passos, MT; Shimizu, MH, 2015
)
1.86
" However, determining the precise dosage for satisfactory efficacy and few side effects are still challenging."( A new method for using radiopaque sclerosing foam to treat venous malformations.
Chen, AW; Li, K; Liu, SH; Liu, YR, 2015
)
0.42
" The renal function was evaluated by (1) the dosage of plasmatic creatinine, (2) the GFR estimated with the Cockroft-Gault, Modification of Diet in Renal Disease (MDRD), and chronic kidney disease epidemiology collaboration (CKD-EPI) formulas, (3) the creatinine clearance (CC), and (4) the direct measurement of the GFR with a reference method (iohexol clearance)."( Preoperative Evaluation of the Renal Function before the Treatment of Abdominal Aortic Aneurysms.
Alvarez, JC; Coggia, M; Coscas, R; Goeau-Brissonniere, O; Javerliat, I; Massy, Z; Sartorius, A; Vilaine, E; Wagner, S, 2017
)
0.63
"To evaluate concordance between glomerular filtration rate (GFR) estimates (Cockcroft and Gault, modification of diet in renal diseases, chronic kidney disease epidemiology study group equations) for drug dosing in HIV-infected patients."( CKD-EPI equation: A suitable Glomerular Filtration Rate estimate for drug dosing in HIV-infected patients.
Botelho-Nevers, E; Cazorla, C; Delanaye, P; Fafin, C; Frésard, A; Gagneux-Brunon, A; Guglielminotti, C; Lucht, F; Mariat, C; Moranne, O, 2017
)
0.46
"To compare the magnitude and interpatient variability in normalized mean hepatic enhancement (MHE) indices when dosing contrast media (CM) according to total body weight (TBW) and lean body weight (LBW)."( Dosing Iodinated Contrast Media According to Lean Versus Total Body Weight at Abdominal CT: A Stratified Randomized Controlled Trial.
Abdolell, M; Costa, AF; Peet, K, 2020
)
0.56
"TBW- and LBW-based CM dosing yield a similar magnitude and interpatient variability in normalized MHE indices at routine abdominal CT."( Dosing Iodinated Contrast Media According to Lean Versus Total Body Weight at Abdominal CT: A Stratified Randomized Controlled Trial.
Abdolell, M; Costa, AF; Peet, K, 2020
)
0.56
" In our study, dehydration duration and the iohexol dosage were found to be the two most important factors to develop a rat CIN model."( A novel rat model of contrast-induced nephropathy based on dehydration.
Chen, LH; Cheng, WJ; Hu, C; Li, DY; Liu, K; Wang, JL; Xie, YL; Yin, WJ; Zhou, G; Zhou, LY; Zuo, SR; Zuo, XC, 2019
)
0.78
"Although proximal tubular secretion is the primary mechanism of kidney drug elimination, current kidney drug dosing strategies are on the basis of eGFR."( Prediction of Kidney Drug Clearance: A Comparison of Tubular Secretory Clearance and Glomerular Filtration Rate.
Brauchla, CC; Chen, Y; de Boer, I; Heckbert, SR; Himmelfarb, J; Hoofnagle, AN; Kestenbaum, BR; Manahan, L; Phillips, B; Shireman, LM; Yeung, CK; Zelnick, LR, 2021
)
0.62
"There was no statistically significant difference in age, weight, body mass index or CM dosing (p > 0."( Contrast media injection protocol for portovenous phase abdominal CT: does a fixed injection duration improve hepatic enhancement over a fixed injection rate?
Costa, AF; Peet, K, 2021
)
0.62
" We developed a population pharmacokinetic model and limited sampling schedules, implemented in the online InsightRX precision dosing platform, to facilitate pragmatic iohexol GFR assessment."( Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting.
Dalton, RN; Dam, RE; de Fijter, JW; de Vries, APJ; Engbers, AGJ; Guchelaar, HJ; Keizer, RJ; Moes, DJAR; Swen, JJ; van der Boog, PJM; Zwart, TC, 2021
)
1.12
"Therapeutic drug monitoring (TDM) aims at individualising a dosage regimen and is increasingly being performed by estimating individual pharmacokinetic parameters via empirical Bayes estimates (EBEs)."( "De-Shrinking" EBEs: The Solution for Bayesian Therapeutic Drug Monitoring.
Baklouti, S; Concordet, D; Gandia, P, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
radioopaque mediumA substance having the property of absorbing, and therefore being opaque to, electromagnetic radiation, particularly X-rays.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
benzenedicarboxamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency5.01190.004110.890331.5287AID504467
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency7.43340.001022.650876.6163AID1224838; AID1224893
gemininHomo sapiens (human)Potency2.05960.004611.374133.4983AID624296
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency12.58930.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,595)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990520 (11.32)18.7374
1990's1050 (22.85)18.2507
2000's1047 (22.79)29.6817
2010's1752 (38.13)24.3611
2020's226 (4.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.29 (24.57)
Research Supply Index8.69 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index124.73 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials744 (14.32%)5.53%
Reviews102 (1.96%)6.00%
Case Studies444 (8.55%)4.05%
Observational24 (0.46%)0.25%
Other3,882 (74.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]